Trial Profile
A Randomized, Double-blind, Placebo-controlled Phase I Study to Assess Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of SH229 in Patients With Hepatitis C Virus (HCV) Infection
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 04 Sep 2018
Price :
$35
*
At a glance
- Drugs SH-229 (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Therapeutic Use
- Sponsors Nanjing Sanhome Pharmaceutical
- 24 Aug 2018 Status changed from recruiting to completed.
- 24 Jul 2018 New trial record